Skip to main content

Table 3 Individual pathologic characteristics by region

From: Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China

  Total Beijing
(North)
Liaoning
(Northeast)
Hunan
(Central)
Guangdong
(South)
Zhejiang
(East)
Shannxi
(Northwest)
Sichuan
(Southwest)
χ2 P-value
Pathological Characteristics Total N = 4211 Total N = 641 Total N = 832 Total N = 546 Total N = 604 Total N = 606 Total N = 483 Total N = 499   
  N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)   
Type of Postoperative Pathological Diagnosis (1)         
   Carcinoma in Situ (CIS) 143 (3.4) 61 (9.5) 22 (2.6) 17 (3.1) 19 (3.1) 7 (1.2) 5 (1.0) 12 (2.4) 169.1 < 0.001
   Invasive Ductal Carcinoma 3471 (82.4) 528 (82.4) 583 (70.1) 504 (92.4) 528 (87.4) 523 (86.3) 406 (84.1) 399 (80.0)   
   Other Invasive Carcinoma 385 (9.1) 47 (7.3) 87 (10.5) 21 (3.8) 29 (4.8) 59 (9.7) 70 (14.5) 72 (14.4)   
   Other 15 (0.4) 5 (0.8) 0 (0.0) 1 (0.2) 4 (0.7) 0 (0.0) 2 (0.4) 3 (0.6)   
   Unavailable 197 (4.7) - 140 (16.8) 3 (0.5) 24 (4.0) 17 (2.8) - 13 (2.6))   
Pathological stage (2)           
   Stage 0 39 (0.9) 7 (1.1) 13 (1.6) 6 (1.1) 8 (1.3) 4 (0.7) 0 (0.0) 1 (0.2) 450.5 < 0.001
   Stage I 663 (15.7) 172 (26.8) 131 (15.7) 73 (13.4) 98 (16.2) 95 (15.7) 77 (15.9) 17 (3.4)   
   Stage II 1891 (44.9) 280 (43.7) 323 (38.8) 400 (73.3) 243 (40.2) 239 (39.4) 170 (35.2) 236 (47.3)   
   Stage III 788 (18.7) 93 (14.5) 119 (14.3) 53 (9.7) 117 (19.4) 152 (25.1) 127 (26.3) 127 (25.5)   
   Stage IV 113 (2.7) 2 (0.3) 4 (0.5) 3 (0.5) 20 (3.4) 5 (0.8) 56 (11.6) 23 (4.6)   
   Unavailable 717 (17.1) 87 (13.6) 242 (29.1) 11 (2.0) 118 (19.5) 111 (18.3) 53 (11.0) 95 (19.0)   
ER/PR test           
   Performed 3555 (84.4) 616 (96.1) 711 (85.5) 535 (98.0) 511 (84.6) 462 (76.2) 282 (58.4) 438 (87.8) 483.2 < 0.001
   Not performed 471 (11.2) 24 (3.7) 85 (10.2) 8 (1.5) 54 (8.9) 67 (11.1) 192 (39.8) 41 (8.2)   
   Unknown 185 (4.4) 1 (0.2) 36 (4.3) 3 (0.5) 39 (6.5) 77 (12.7) 9 (1.8) 20 (4.0)   
Her-2 test           
   Performed 3251 (77.2) 609 (95.0) 693 (83.3) 533 (97.6) 469 (77.6) 424 (70.0) 241 (49.9) 282 (56.5) 640.2 < 0.001
   Not performed 762 (18.1) 31 (4.8) 98 (11.8) 8 (1.5) 99 (16.4) 98 (16.1) 227 (47.0) 201 (40.3)   
   Unknown 198 (4.7) 1 (0.2) 41 (4.9) 5 (0.9) 36 (6.0) 84 (13.9) 15 (3.1) 16 (3.2)   
ER/PR status (3)           
   ER+&PR+ 1691 (47.6) 373 (60.6) 318 (44.7) 244 (45.6) 241 (47.2) 221 (47.8) 109 (38.7) 185 (42.2) 121.0 < 0.001
   ER+&PR- 337 (9.5) 44 (7.1) 79 (11.1) 54 (10.1) 37 (7.2) 41 (8.9) 31 (11.0) 51 (11.6)   
   ER-&PR+ 367 (10.3) 47 (7.6) 108 (15.2) 32 (6.0) 75 (14.7) 34 (7.4) 37 (13.1) 34 (7.8)   
   ER-&PR- 1139 (32.0) 146 (23.7) 206 (29.0) 203 (37.9) 152 (29.7) 165 (35.7) 101 (35.8) 166 (37.9)   
   Unavailable 21 (0.6) 6 (1.0) - 2 (0.4) 6 (1.2) 1 (0.2) 4 (1.4) 2 (0.5)   
Her-2 status (4)           
   Her-2 + 736 (22.6) 286 (47.0) 36 (5.2) 156 (29.3) 90 (19.2) 68 (16.0) 29 (12.0) 71 (25.2) 339.6 < 0.001
   Her-2 - 2113 (65.0) 299 (49.1) 545 (78.6) 314 (58.9) 337 (71.9) 317 (74.8) 181 (75.1) 120 (42.6)   
   Uncertain/unavailable 402 (12.4) 24 (3.9) 112 (16.2) 63(11.8) 42 (9.1) 39 (9.2) 31 (12.9) 91 (32.2)   
  1. (1): carcinoma in situ: ductal carcinoma in situ, lobular carcinoma in situ, microinvasive ductal carcinoma, and Paget's disease invasive ductal carcinoma: pure invasive ductal carcinoma and mixed invasive ductal carcinoma other invasive carcinomas: invasive labular carcinoma, tubular carcinoma, medullary carcinoma, mucin carcinoma, and other invasive carcinomas
  2. (2): according to the AJCC/UICC TNM system
  3. (3): ER/PR status was based on all breast cancer cases tested for ER/PR
  4. (4): Her-2 status was based on all breast cancer cases tested for Her-2
\